Khloud Alsaadi

Dr. Khloud Alsaadi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
AAAshwag J. Alzahrani
Ashwag J. Alzahrani
BHBasma Mohmmed Al hebshi
Basma Mohmmed Al hebshi
Zolfekar YahiaZolfekar Yahia
Zolfekar Yahia
EAEffat Al-Judaibi
Effat Al-Judaibi
KAKhloud Alsaadi
Khloud Alsaadi
Awatif AlJudaibiAwatif AlJudaibi
Awatif AlJudaibi
Inflammatory bowel disease (IBD) is a chronic condition that includes two main types, Crohn’s disease (CD) and ulcerative colitis (UC), involving inflammation of the gastrointestinal (GI) tract. The exact cause of IBD is unknown but could be a combination of genetic, environmental, and immune system factors. This study investigated the impact of IBD on microbiota diversity by evaluating the differences in microbial composition and the microbiota of a control group (A) of healthy individuals and a group (B) of IBD patients. Sixty biopsies were collected from participants recruited from hospitals in Makkah, Saudi Arabia. Biopsy specimens were taken during colonoscopy examination, and bacterial identification was performed by extracting ribosomal DNA from sigmoid colon biopsies using a DNeasy Blood & Tissue Kit. Metagenomics and bioinformatics analyses were then conducted to analyze and compare the microbiota in the two groups. The results showed that the varieties of core microbiome species were 3.81% greater in the IBD patients than in the members of the control group. Furthermore, the differences between the groups were significantly greater than the variations within each group. Differences between the two groups were detected in the relative abundance of Clostridium nexile, Ruminococcus gnavus, Ruminococcus faecis, and Escherichia coli. These results indicate that microbiota could play a role in the pathogenesis of IBD and suggest that microbial diversity can serve as a biomarker for diagnosing the disease and monitoring its progression.

17 January 2026 in Journal of Nanoparticle Research
Verified
Journal Article
Closed access
PDF file
MTManal Mohamed Elhassan Taha
Manal Mohamed Elhassan Taha
SASiddig Ibrahim Abdelwahab
Siddig Ibrahim Abdelwahab
Abdullah FarasaniAbdullah Farasani
Abdullah Farasani
JMJobran M Moshi
Jobran M Moshi
NKNizar A. Khamjan
Nizar A. Khamjan
AAAbdulaziz Alarifi
Abdulaziz Alarifi

23 December 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MTManal Mohamed Elhassan Taha
Manal Mohamed Elhassan Taha
SASiddig Ibrahim Abdelwahab
Siddig Ibrahim Abdelwahab
HMHazem Mathkour
Hazem Mathkour
EAEDROUS ALAMER
EDROUS ALAMER
SASaleh Abdullah
Saleh Abdullah
BABandar Mushin Alamri
Bandar Mushin Alamri
Background Graphene-based nanomaterials are increasingly explored for cancer diagnosis and therapy, yet a comprehensive mapping of their scholarly landscape is lacking. Methods On 13 March 2025, a total of 4917 records (2016–2025) were retrieved from the Scopus database using a multistep search strategy. Bibliometric indicators were analyzed with Bibliometrix (R-package), VOSviewer, and CiteSpace to evaluate research growth, collaboration, intellectual structures, and thematic evolution. Results Publications grew at an annual rate of 2.97%, with China leading in both productivity and citations. Bradford’s Law identified 21 core journals, and leading contributors included LI Y and ZHANG Y. Collaboration networks showed dense interinstitutional and international links, particularly across Asia. Keyword and thematic analyses highlighted enduring focuses such as “graphene oxide,” “drug delivery,” and “biosensors,” while emerging trends included “plasmon resonance biosensor,” “brain tumor detection,” and advanced therapeutic applications. Co-citation and overlay mapping revealed conceptual shifts toward precision diagnostics and targeted therapies. Conclusion This study provides the first integrated bibliometric roadmap of graphene-based cancer research (2016–2025), outlining its growth trajectory, knowledge structures, and evolving themes. Findings inform researchers, funding agencies, and policymakers on current strengths, translational challenges, and priority directions for advancing graphene-based innovations in oncology.